Walleye Capital’s Lexeo Therapeutics LXEO Stock Holding History

Walleye Capital’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-61,930	Closed	-$407K	–	4738
2024 Q4	$407K	Buy	+61,930	New	+$488K	﹤0.01%	3153

Other funds holding LXEO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Capital's LXEO Position: Q1 2025 in Review

Walleye Capital sold out of Lexeo Therapeutics (LXEO) in Q1 2025, closing a stake of 61,930 shares — an estimated $407K sold.

Walleye Capital first reported a position in LXEO in Q4 2024 and held it in 1 quarter. The position peaked at $407K in Q4 2024. 88 funds tracked by Wall St. Rank hold LXEO as of Q1 2025.

Walleye Capital reported no remaining Lexeo Therapeutics position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 61,930 Lexeo Therapeutics shares in Q1 2025, an estimated $407K.
Walleye Capital first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 1 quarter.
Walleye Capital's Lexeo Therapeutics position peaked at $407K in Q4 2024.
88 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.